Chamath Palihapitiya's New SPAC Bet: Learning From Past Mistakes or Repeating History?

The infamous SPAC boom of 2020-2021 left a trail of disappointed investors. Now, more than three years after his last blank-check company venture, prominent SPAC sponsor Chamath Palihapitiya is launching yet another one. He’s established American Exceptionalism Acquisition Corp. A with plans to raise $250 million, operating under the ticker symbol AEXA. The question on many investors’ minds: Is this truly a different approach, or are we about to see the old playbook all over again?

The American Exceptionalism SPAC: A $250 Million Bet on Four Strategic Sectors

Palihapitiya’s new SPAC will seek acquisition targets in one of four carefully selected areas: energy production, artificial intelligence, decentralized finance, and defense. The rationale behind this strategy is grounded in observable market realities. The SPAC sponsor correctly notes that over 700 private companies now carry billion-dollar valuations, while the total number of publicly traded companies in the United States has declined by roughly 2,000 since the 1990s. In essence, there’s substantial pent-up demand from growth-stage companies seeking alternatives to the traditional IPO route.

Unlike a typical IPO process, which requires years of preparation and SEC scrutiny, a SPAC merger allows companies to go public more quickly. This appeals to founders and investors alike—at least in theory. The reality, as Palihapitiya’s own track record demonstrates, is considerably messier.

How This New SPAC Differs Structurally From Previous Blank-Check Companies

On the surface, there are meaningful differences between this new vehicle and the SPAC deals that proliferated during the 2020-2021 frenzy. Most of those earlier deals were structured as “units” combining shares with warrants—stock purchase rights that created additional incentives for early investors but often resulted in massive dilution. Palihapitiya’s new SPAC eliminates warrants entirely, addressing one of the structural problems that plagued prior iterations.

More significantly, the sponsor’s founder shares—the large equity stake that Palihapitiya receives for organizing the deal—come with performance conditions. These shares only vest if the stock price rises by 50% following the merger announcement. If the target company underperforms, Palihapitiya’s own equity becomes worthless. This vesting mechanism theoretically aligns the sponsor’s financial interests with those of ordinary shareholders, creating an incentive for the sponsor to find a genuinely attractive acquisition target rather than simply closing a deal quickly.

These structural improvements matter. They represent a genuine attempt to address misaligned incentives that plagued the 2020-2021 SPAC cohort, where sponsors often profited regardless of investor outcomes.

The Uncomfortable Historical Record: A Cautionary Tale

Yet structural tweaks cannot erase history. During the initial SPAC explosion, Palihapitiya directly sponsored six blank-check companies operating under the “IPO” series—IPOA through IPOF. (He once joked about reserving ticker symbols all the way to IPOZ, though the SPAC craze fizzled before reaching that far.)

The performance results tell a sobering story:

(Data as of August 2025)

Only one of the six SPAC deals generated positive returns for buy-and-hold investors. If an investor had committed $10,000 to each SPAC before any merger was announced—a total of $60,000—that portfolio would have contracted to approximately $46,750 today. Two SPACs dissolved without finding targets, returning capital to shareholders with no gains.

Palihapitiya also sponsored four biotechnology-focused SPACs in 2021. Two collapsed and returned capital. The other two identified targets, but both trade well below their $10 initial offering price.

Even SoFi Technologies, the sole success story from Palihapitiya’s portfolio, was still years away from achieving operational milestones when it merged with IPOE. The company was pursuing a bank charter that hadn’t yet materialized—a reminder that SPAC targets are inherently early-stage ventures with uncertain outcomes.

The Fundamental SPAC Risk: Betting on a Concept, Not a Company

Before considering whether to invest in American Exceptionalism, prospective shareholders should confront an uncomfortable truth: when you buy a SPAC before any merger announcement, you’re not investing in an actual business. You’re making a speculative wager that Palihapitiya will identify a compelling acquisition target at a reasonable valuation.

This is fundamentally different from traditional equity investment. You have no visibility into which company will eventually be targeted. The deal could be announced tomorrow or 18 months from now—or might never happen at all. Even assuming a competent sponsor, timing and valuation risk remain substantial.

Additionally, SPAC targets are typically early-stage growth companies with limited operating history, minimal cash flow, and unproven business models. Established, profitable companies rarely use SPACs to access public markets; they generally opt for traditional IPOs. The few exceptions prove the rule—they’re exotic outliers rather than the norm.

Managing position size becomes essential in this context. An investor might allocate a small percentage of a portfolio to SPAC shares as a speculative holding, understanding that the position could decline substantially or become worthless. But deploying significant capital into blank-check companies before any merger target has been identified violates basic risk management principles.

The Investment Decision: Caveat Emptor

The structural improvements embedded in American Exceptionalism represent genuine progress. Eliminating warrants reduces dilution. Tying founder shares to performance creates alignment. These aren’t trivial enhancements; they directly address flaws that haunted previous SPAC cohorts.

But none of these modifications can overcome the irreducible reality of what a pre-merger SPAC actually is: a highly speculative investment vehicle. Palihapitiya’s mixed track record across numerous SPAC deals serves as a sobering reminder that execution remains uncertain and outcomes highly variable.

If you choose to participate in this new SPAC, do so with clear eyes and modest position sizing. Understand that you’re accepting substantial uncertainty in exchange for the possibility of accessing an early-stage growth company that might—just might—eventually deliver outsized returns. History suggests this is a low-probability outcome for most investors.